Zeng et al. [130] evaluated the feasibility of CD22/CD19-targeted CAR-T-cell sequential therapy in 14 patients with aggressive r/r B-cell lymphoma with GI involvement. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.